US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SIMPLIFY MANAGED FUTURES STRATEGY ETF

27.01

-0.8800-3.16%

Post-market: 26.59-0.4225-1.56%19:30 EDT

Volume:269.21K

Turnover:7.33M

Market Cap:1.55B

PE:- -

High:27.49

Open:27.38

Low:26.95

Close:27.89

52wk High:32.76

52wk Low:25.39

Shares:57.38M

Float Shares:57.38M

Volume Ratio:0.83

T/O Rate:0.47%

Dividend:1.39

Dividend Rate:5.16%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Goldman Sachs Trader Warns: Market Correction Not Over, CTA Strategies Still Face Nearly $100 Billion in Pending Sell Pressure

Press Release: Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Oil Price Surge Triggers Asia-Pacific Market Plunge

Hedge Funds Face Largest Drawdown Since April Last Year, Particularly Equity Long-Short Strategies Overweight in Europe and Korea

Systemic Selling Pressure Set to Intensify as Major Banks Warn of Structural Vulnerabilities

Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders

Press Release: Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Press Release: Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/CTA/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CTA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTA\",,,,,undefined,":{"symbol":"CTA","market":"US","secType":"STK","nameCN":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","latestPrice":27.01,"timestamp":1787688000000,"preClose":27.89,"halted":0,"volume":269207,"hourTrading":{"tag":"盘后","latestPrice":26.5875,"preClose":27.01,"latestTime":"19:30 EDT","volume":2388,"amount":63967.045,"timestamp":1787700602759,"change":-0.4225,"changeRate":-0.015642,"amplitude":0.015642},"delay":0,"changeRate":-0.031552527787737504,"floatShares":57375001,"shares":57375001,"eps":0,"marketStatus":"Not Yet Opened","change":-0.88,"latestTime":"08-25 16:00:00 EDT","open":27.38,"high":27.485,"low":26.95,"amount":7327880.495715,"amplitude":0.019183,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787731200000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":27.89,"sharesOutstanding":45800001,"nav":27.9302,"aum":1586282159.74,"dividendRate":0.051573,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":27.89,"preClose":27.89,"latestTime":"07:37 EDT","volume":781,"amount":21540.270532,"timestamp":1787657857534,"change":0,"changeRate":0,"amplitude":0.014701},"postHourTrading":{"tag":"盘后","latestPrice":26.5875,"preClose":27.01,"latestTime":"19:30 EDT","volume":2388,"amount":63967.045,"timestamp":1787700602759,"change":-0.4225,"changeRate":-0.015642,"amplitude":0.015642},"volumeRatio":0.828897,"impliedVol":0.341,"impliedVolPercentile":0.9641},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTA\",,,,,undefined,":{"symbol":"CTA","floatShares":57375001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.828897,"shares":57375001,"dividePrice":1.393,"high":27.485,"amplitude":0.019183,"preClose":27.89,"low":26.95,"week52Low":25.39,"pbRate":"--","week52High":32.76,"institutionHeld":0,"latestPrice":27.01,"eps":0,"divideRate":0.051573,"volume":269207,"delay":0,"ttmEps":0,"open":27.38,"prevYearClose":27.26,"prevWeekClose":28.55,"prevMonthClose":27.14,"prevQuarterClose":25.94,"fiveDayClose":27.93,"twentyDayClose":26.32,"sixtyDayClose":28.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTA\",params:#limit:5,,,undefined,":[{"date":"2026-07-28","symbol":"CTA","amount":0.13,"announcedDate":"2026-07-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-28","defaultRemindTime":1785245400000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-31","payableDate":"2026-07-28","currency":"USD","dateTimestamp":1785211200000,"payDate":"2026-07-31"},{"date":"2026-06-25","symbol":"CTA","amount":0.13,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-25","defaultRemindTime":1782394200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-30","payableDate":"2026-06-25","currency":"USD","dateTimestamp":1782360000000,"payDate":"2026-06-30"},{"date":"2026-05-26","symbol":"CTA","amount":0.15,"announcedDate":"2026-05-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-26","defaultRemindTime":1779802200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-29","payableDate":"2026-05-26","currency":"USD","dateTimestamp":1779768000000,"payDate":"2026-05-29"},{"date":"2026-04-27","symbol":"CTA","amount":0.15,"announcedDate":"2026-04-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-04-27","defaultRemindTime":1777296600000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-30","payableDate":"2026-04-27","currency":"USD","dateTimestamp":1777262400000,"payDate":"2026-04-30"},{"date":"2026-03-26","symbol":"CTA","amount":0.15,"announcedDate":"2026-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-26","defaultRemindTime":1774531800000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-31","payableDate":"2026-03-26","currency":"USD","dateTimestamp":1774497600000,"payDate":"2026-03-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTA\",market:\"US\",,,undefined,":[{"executeDate":"2022-08-26","recordDate":"2022-08-29","paymentDate":"2022-08-31","value":0.15,"currency":"USD"},{"executeDate":"2022-09-27","recordDate":"2022-09-28","paymentDate":"2022-09-30","value":0.15,"currency":"USD"},{"executeDate":"2022-10-26","recordDate":"2022-10-27","paymentDate":"2022-10-31","value":0.15,"currency":"USD"},{"executeDate":"2022-11-25","recordDate":"2022-11-28","paymentDate":"2022-11-30","value":0.15,"currency":"USD"},{"executeDate":"2022-12-27","recordDate":"2022-12-28","paymentDate":"2022-12-30","value":1.11096,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTA\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1108409237","title":"Goldman Sachs Trader Warns: Market Correction Not Over, CTA Strategies Still Face Nearly $100 Billion in Pending Sell Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=1108409237","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108409237?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:44","pubTimestamp":1773668691,"startTime":"0","endTime":"0","summary":"The U.S. stock market correction has not yet reached its bottom, with mechanical selling pressure continuing to build. The latest analysis from Goldman Sachs' derivatives and trading team indicates...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868837136.USD","LU0345770308.USD","LU2237443465.HKD","IE00BSNM7G36.USD","LU2237438978.USD","BK4550","LU1668664300.SGD","IE00B19Z3B42.SGD","LU2265009873.SGD","IE00B19Z3581.USD","LU0048573561.USD","BK4516","LU2237443978.SGD","LU0251142724.SGD","LU2237443622.USD","IE0002270589.USD","IE0034235188.USD","LU1868837300.USD","LU0251131958.USD","LU0742534661.SGD","IE0004086264.USD","LU2471134523.USD","LU2471134879.HKD","LU2750360641.GBP","LU2471134796.USD","LU2750360997.AUD","LU2237443549.SGD","GSX","LU1894683264.USD","LU2237443382.USD","LU0106831901.USD","LU1868836591.USD","BK4585","LU0345770993.USD","LU0061475181.USD","IE00BFXG1179.USD","LU1804176565.USD","LU2237443895.HKD","LU1791807156.HKD","LU1868836914.USD","LU0096364046.USD","LU1868836757.USD","BK4504","LU2471134952.CNY","BK4552","LU1894683348.USD","GS","CTA","IE0004091025.USD","BK4588","BK4533","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619500464","title":"Press Release: Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2619500464","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619500464?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:00","pubTimestamp":1773662400,"startTime":"0","endTime":"0","summary":"Coya Therapeutics, Inc.  , a clinical-stage biotechnology company developing biologics intended to enhance T-cell  function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for the year ended December 31, 2025.--  Successfully launched the ALSTARS Phase 2 trial evaluating COYA. 302 for the treatment of ALS and now actively enrolling and dosing. patients across 25 clinical sites in the U.S. and Canada.--  Clinical Trial Application  acceptance from Health Canada. to proceed with the COYA 302 ALSTARS Phase 2 trial in Canada.--  Announced COYA 302 ALS trial acceptance by NEALS as a. --  Announced U.S. FDA acceptance of Investigation New Drug . Application for COYA 302 for the treatment of frontotemporal. and brain anti-inflammatory activity and enhanced Treg cell. function in an in vivo lipopolysaccharide  preclinical mouse. --  Published results in Frontiers in Immunology linking. inflammation and oxidative stress to the progre","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4007","CTA","BK4139","COYA","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195532110","title":"Oil Price Surge Triggers Asia-Pacific Market Plunge","url":"https://stock-news.laohu8.com/highlight/detail?id=1195532110","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195532110?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:26","pubTimestamp":1773311161,"startTime":"0","endTime":"0","summary":"Oil price shocks continue to reverberate across markets. During early Asia-Pacific trading, Brent crude futures extended gains, surging by 10% intraday to reach $101.59 per barrel. Reports indicate...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102480808","title":"Hedge Funds Face Largest Drawdown Since April Last Year, Particularly Equity Long-Short Strategies Overweight in Europe and Korea","url":"https://stock-news.laohu8.com/highlight/detail?id=1102480808","media":"Deep News","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102480808?lang=en_us&edition=fundamental","pubTime":"2026-03-12 08:10","pubTimestamp":1773274235,"startTime":"0","endTime":"0","summary":"Hedge funds are experiencing their most severe drawdown since last year's tariff disputes, with concentrated unwinding of crowded trades causing significant losses for this fast-money sector....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443622.USD","LU2242649171.HKD","LU0496365809.HKD","LU1629891620.HKD","LU2417539215.USD","LU2430703251.USD","BK4516","IE00BBT3K403.USD","LU1670628061.USD","IE00BLSP4239.USD","LU0211326755.USD","LU0006306889.USD","LU0868494708.USD","LU1548497426.USD","BK4504","LU2023250330.USD","LU2456880835.USD","LU2756315664.SGD","LU0976567544.SGD","LU1496350171.SGD","LU0203345920.USD","LU0345769128.USD","LU1032466523.USD","LU0964807845.USD","IE00BHPRN162.USD","LU0203347892.USD","LU2357305700.SGD","LU0238689110.USD","LU1244550577.SGD","LU1894683264.USD","IE00BJTD4V19.USD","BK4588","JPM","LU2552382215.SGD","LU1363072403.SGD","LU2592432038.USD","LU1244550221.USD","BK4207","LU0106831901.USD","LU0640476718.USD","LU1162221912.USD","LU0106261372.USD","BK4566","LU0345770308.USD","LU0170899867.USD","IE00BZ1G4Q59.USD","LU1119994496.HKD","IE00B3S45H60.SGD","LU2264538146.SGD","LU0320765489.SGD","LU1267930490.SGD","LU2430703095.HKD","LU0265550946.USD","LU2462157665.USD","LU2106854487.HKD","LU2505996509.AUD","IE00BLSP4452.SGD","LU1551013342.USD","LU1720051108.HKD","LU0265550359.USD","LU2237443549.SGD","LU2211815571.USD","LU1366192091.USD","IE000M9KFDE8.USD","IE00BKVL7J92.USD","IE00BYXW3230.USD","LU0942090050.USD","LU0971096721.USD","LU1244550494.USD","LU1988902786.USD","LU2552382058.USD","LU0234572021.USD","BK4534","LU0070302665.USD","LU0345769631.USD","JPMO","IE0034235295.USD","LU1917777945.USD","LU2237443382.USD","LU0417517546.SGD","LU2552382132.HKD","LU0345770993.USD","LU1116320901.HKD","LU1670627923.USD","LU0215105999.USD","IE00BJLML261.HKD","LU0943347566.SGD","LU0211326839.USD","LU2023250504.SGD","LU2237443895.HKD","IE00BN8TJ469.HKD","LU1261432733.SGD","IE0034235188.USD","IE0034235303.USD","LU1084165304.USD","LU0310799852.SGD","IE00BJTD4N35.SGD","LU2505996681.GBP","LU1116320737.USD","LU1894683348.USD","LU0211328371.USD","SG9999002232.USD","LU0323591593.USD","LU1974910355.USD","LU2756315318.SGD","LU2746668974.SGD","LU0820561909.HKD","LU0208291251.USD","LU1280957306.USD","LU0211331839.USD","LU0251132253.USD","LU1145028129.USD","CTA","LU2237443465.HKD","LU1496350502.SGD","LU2054465674.USD","LU0820562030.AUD","LU1064131342.USD","LU0048584097.USD","LU0787776722.HKD","LU0149725797.USD","LU0683600562.USD","LU1914381329.SGD","LU2381873111.SGD","BK4533","LU2746668461.USD","SG9999002224.SGD","IE00B1BXHZ80.USD","LU2236285917.USD","IE00BDCRKT87.USD","LU0256863811.USD","BK4550","LU1551013425.SGD","IE00BDRTCR15.USD","LU1720051017.SGD","LU2213496289.HKD","LU2023250843.SGD","LU2237443978.SGD","LU0267386448.USD","LU0689472784.USD","BK4581","LU2430703178.SGD","IE00B775SV38.USD","IE00B1XK9C88.USD","LU0320765646.SGD","IE00BFXG1179.USD","IE00BWXC8680.SGD","LU0211327993.USD","LU0868494617.USD","LU1668664300.SGD","LU0820561818.USD","LU0882574139.USD","BK4585","IE00BKDWB100.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183313210","title":"Systemic Selling Pressure Set to Intensify as Major Banks Warn of Structural Vulnerabilities","url":"https://stock-news.laohu8.com/highlight/detail?id=1183313210","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183313210?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:48","pubTimestamp":1773143322,"startTime":"0","endTime":"0","summary":"Despite a brief lift in risk sentiment following signals of de-escalation in the Middle East, recent trading desk alerts from Goldman Sachs and JPMorgan indicate that deeper structural issues in the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618625435","title":"Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2618625435","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618625435?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:00","pubTimestamp":1773057600,"startTime":"0","endTime":"0","summary":"-- Company will trade on Nasdaq under trading symbol \"DMRA\" effective March 10, 2026 -- -- On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251772/0/en/Galecto-Announces-Name-Change-to-Damora-Therapeutics-with-Mission-to-Fundamentally-Redefine-Care-for-Patients-with-Blood-Disorders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4561","BK4007","BK4581","DMRA","BK4106","ET","BK4539","BK4588","BK4226","BK4590","GLTO","IND","BK4144","BK4585","LENZ","XELA","CTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617866576","title":"Press Release: Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2617866576","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617866576?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:05","pubTimestamp":1772744700,"startTime":"0","endTime":"0","summary":"Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus  in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026. Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care. Expanded Antiviral Pipeline with New Hepatitis E Virus  Program; Lead Product Candidate AT-587 Expected to Enter Clinic Mid-2026. Atea continues to advance its global Phase 3 program evaluating the fixed-dose combination  of bemnifosbuvir  and ruzasvir  for the treatment of chronic HCV. The global Phase 3 program consists of two open-label controlled trials: C-BEYOND in North America and C-FORWARD outside North America. In 2025, Atea advanced enrollment across both trials. The Company completed C-BEYOND enrollment in December 2025 with over 880 patients and C-FORWARD is expected to complete enrollment mid-2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","R","DDI","BK4085","BK4232","BK4022","AVIR","CTA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616349328","title":"Press Release: Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2616349328","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616349328?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:00","pubTimestamp":1772542800,"startTime":"0","endTime":"0","summary":"-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --. -- Ongoing engagement with FDA for PM359 in CGD; plan to submit BLA following final alignment --. -- Prime Medicine reported cash, cash equivalents, investments, and restricted cash of $191M providing cash runway into 2027 --. CAMBRIDGE, Mass., March 03, 2026  -- Prime Medicine, Inc. , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2025 and provided a business update.Prime Medicine is advancing in vivo gene editing programs aimed at treating two of the most significant genetic liver disorders: Wilson Disease  and Alpha--1 Antitrypsin Deficiency . Prime Medicine anticipates submitting an investigational new drug  and/or clinical trial application  for its anchor WD program  in the first half","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA","BK4139","ASH","PRME","LU2463526074.USD","BK4195","BK4109","IND","BK4093","WD","BK4585","BK4229","CF","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":5,"totalSize":88,"code":"91000000","status":"200"}]}}